Switzerland-based Novartis has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for crizanlizumab (SEG101) in order to prevent vaso-occlusive crises in patients of all genotypes with sickle cell disease, it was reported yesterday.
The product is a humanised anti-P-selectin monoclonal antibody being studied to restrict vaso-occlusive crises in sickle cell disease.
The status has been offered based on positive data from the phase II Sustain study, which compared the P-selectin inhibitor crizanlizumab against placebo in patients with sickle cell disease. The study indicated that crizanlizumab decreased the median annual rate of vaso-occlusive crises leading to health care visits by 45.3% compared to placebo in patients with or without hydroxyurea therapy, according to the company. The sustain study also showed that crizanlizumab significantly increased the percentage of patients who did not experience any vaso-occlusive crises against placebo during treatment.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial